Jeff Martin
Stock Analyst at Roth Capital
(4.40)
# 349
Out of 5,120 analysts
66
Total ratings
61.29%
Success rate
16.67%
Average return
Main Sectors:
Stocks Rated by Jeff Martin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OSIS OSI Systems | Maintains: Buy | $292 → $295 | $252.72 | +16.73% | 18 | Jan 30, 2026 | |
| BWMN Bowman Consulting Group | Maintains: Buy | $45 → $50 | $34.58 | +44.59% | 6 | Dec 9, 2025 | |
| PERI Perion Network | Reiterates: Buy | $14 → $15 | $8.73 | +66.09% | 10 | Nov 13, 2025 | |
| NSP Insperity | Maintains: Buy | $85 → $74 | $43.15 | +71.49% | 9 | Aug 4, 2025 | |
| FC Franklin Covey Co. | Maintains: Buy | $30 → $27 | $20.65 | +30.75% | 8 | Jul 7, 2025 | |
| TACT TransAct Technologies | Maintains: Buy | $6 → $5 | $3.51 | +42.45% | 1 | May 14, 2025 | |
| BGSF BGSF, Inc. | Maintains: Buy | $12 → $9 | $5.70 | +57.89% | 1 | Mar 20, 2025 | |
| BBSI Barrett Business Services | Maintains: Buy | $43 → $45 | $38.21 | +17.77% | 5 | Nov 7, 2024 | |
| HCKT The Hackett Group | Maintains: Buy | $29 → $30 | $18.70 | +60.43% | 6 | Nov 5, 2024 | |
| GLMD Galmed Pharmaceuticals | Initiates: Buy | $5,760 | $0.67 | +865,544.72% | 2 | Nov 15, 2017 |
OSI Systems
Jan 30, 2026
Maintains: Buy
Price Target: $292 → $295
Current: $252.72
Upside: +16.73%
Bowman Consulting Group
Dec 9, 2025
Maintains: Buy
Price Target: $45 → $50
Current: $34.58
Upside: +44.59%
Perion Network
Nov 13, 2025
Reiterates: Buy
Price Target: $14 → $15
Current: $8.73
Upside: +66.09%
Insperity
Aug 4, 2025
Maintains: Buy
Price Target: $85 → $74
Current: $43.15
Upside: +71.49%
Franklin Covey Co.
Jul 7, 2025
Maintains: Buy
Price Target: $30 → $27
Current: $20.65
Upside: +30.75%
TransAct Technologies
May 14, 2025
Maintains: Buy
Price Target: $6 → $5
Current: $3.51
Upside: +42.45%
BGSF, Inc.
Mar 20, 2025
Maintains: Buy
Price Target: $12 → $9
Current: $5.70
Upside: +57.89%
Barrett Business Services
Nov 7, 2024
Maintains: Buy
Price Target: $43 → $45
Current: $38.21
Upside: +17.77%
The Hackett Group
Nov 5, 2024
Maintains: Buy
Price Target: $29 → $30
Current: $18.70
Upside: +60.43%
Galmed Pharmaceuticals
Nov 15, 2017
Initiates: Buy
Price Target: $5,760
Current: $0.67
Upside: +865,544.72%